- Home
- BLDE vs PVLA Comparison
BLDE vs PVLA Comparison
Compare BLDE & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLDE
- PVLA
- Stock Information
- Founded
- BLDE 2014
- PVLA 2015
- Country
- BLDE United States
- PVLA United States
- Employees
- BLDE N/A
- PVLA N/A
- Industry
- BLDE Aerospace
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- BLDE Consumer Discretionary
- PVLA Health Care
- Exchange
- BLDE Nasdaq
- PVLA Nasdaq
- Market Cap
- BLDE 272.5M
- PVLA 308.2M
- IPO Year
- BLDE N/A
- PVLA N/A
- Fundamental
- Price
- BLDE $2.55
- PVLA $25.45
- Analyst Decision
- BLDE Strong Buy
- PVLA Strong Buy
- Analyst Count
- BLDE 2
- PVLA 7
- Target Price
- BLDE $6.25
- PVLA $44.43
- AVG Volume (30 Days)
- BLDE 642.1K
- PVLA 80.2K
- Earning Date
- BLDE 05-06-2025
- PVLA 05-15-2025
- Dividend Yield
- BLDE N/A
- PVLA N/A
- EPS Growth
- BLDE N/A
- PVLA N/A
- EPS
- BLDE N/A
- PVLA N/A
- Revenue
- BLDE $248,693,000.00
- PVLA N/A
- Revenue This Year
- BLDE $5.21
- PVLA N/A
- Revenue Next Year
- BLDE $8.70
- PVLA N/A
- P/E Ratio
- BLDE N/A
- PVLA N/A
- Revenue Growth
- BLDE 10.44
- PVLA N/A
- 52 Week Low
- BLDE $2.35
- PVLA $6.20
- 52 Week High
- BLDE $5.17
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- BLDE 37.66
- PVLA N/A
- Support Level
- BLDE $2.59
- PVLA N/A
- Resistance Level
- BLDE $2.81
- PVLA N/A
- Average True Range (ATR)
- BLDE 0.21
- PVLA 0.00
- MACD
- BLDE 0.01
- PVLA 0.00
- Stochastic Oscillator
- BLDE 37.38
- PVLA 0.00
About BLDE Blade Air Mobility Inc.
Blade Air Mobility Inc is a technology-powered air mobility platform that provides air transportation and logistics for hospitals and is a transporter of human organs for transplant, and for passengers, with helicopter and fixed-wing services predominantly in the Northeast United States, Southern Europe and Western Canada. The company's operating segments are; Passenger, and Medical. Majority of the revenue for the company is generated from its Medical segment which predominantly consists of transportation of human organs for transplant and the medical teams supporting these services. It also offers additional services including donor logistics coordination and support in evaluating potential donor organs. A substantial portion of the company's revenue is generated from the United States.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.